Monoclonal antibodies |
|
Saturday, 13 April 2002 |
|
Organizer |
A. Bosly (Yvoir, Belgium) |
Therapeutic options of monoclonal antibodies |
|
Session I |
|
| Chairs | A. Bosly (Yvoir, Belgium)G. Salles (Lyon, France) |
| 14.00 – 14.05 |
Introduction A. Bosly (Yvoir, Belgium) |
| 14.05 – 14.30 |
Monoclonal antibodies in lymphoma. Mechanisms of action. G. Salles (Lyon, France) |
| 14.30 – 15.00 |
Rituximab (anti CD 20). Clinical studies. A. Bosly (Yvoir, Belgium) |
| 15.00 – 15.30 |
Herceptin (anti HER2) clinical and medico-economics aspects. V. Trillet-Lenoir (Lyon, France) |
| 15.30 – 15.45 | coffee break |
| 15.45 – 16.15 |
Biologics for the treatment of rhumatoïd arthritis P. Durez (Brussels, Belgium) |
| 16.15 – 16.45 |
GP IIb IIIa Blockade: are they absolute anti-platelet agents? V. Mathieux (Paris, France) |
| 16.45 – 17.00 |
conclusions G. Salles (Lyon, France) |
| 17.00 | end of workshop 18 |
